COST Quantitative Stock Analysis

Costco (COST) received a 77% rating from Validea's Partha Mohanram P/B Growth Investor model, an academically-derived strategy for identifying low book-to-market stocks with sustained growth potential. While this score is just below the 80% threshold for "some interest," the large-cap retail stock demonstrated strong fundamentals, passing tests for return on assets, cash flow, and sales consistency, despite failing criteria related to advertising and R&D expenditures. This assessment indicates COST aligns well with a model designed to identify high-performing growth equities.

Analysis

Costco Wholesale Corporation (COST) scores a 77% rating based on Validea's P/B Growth Investor model, a strategy developed by Partha Mohanram to identify low book-to-market stocks with potential for sustained growth. This score is positioned just below the 80% threshold that the model typically uses to indicate interest in a security. The analysis reveals that COST passes a majority of the model's fundamental tests, showing strength in its book-to-market ratio, return on assets (ROA), cash flow from operations to assets, and low variance in both ROA and sales. These factors point to a financially healthy and operationally consistent business. However, the company fails the model's criteria for Advertising to Assets and Research and Development to Assets. While these are flagged as negatives by the quantitative screen, they may reflect inherent characteristics of Costco's low-cost retail business model rather than fundamental operational weaknesses.

Key Decisions for Investors

• Investors following quantitative growth strategies should note that while COST exhibits strong fundamental traits, its 77% score falls just short of a definitive buy signal under the Mohanram model's specific framework.
• The 'fail' ratings on advertising and R&D should be evaluated within the context of Costco's established low-cost business strategy, as these are likely intentional operational choices rather than indicators of poor capital allocation.
• The strong performance on core metrics like return on assets, cash flow generation, and sales stability provides evidence of robust operational health, which should be a key positive data point for fundamentally-driven investors.